ID   ZR-75-1 Tam2
DR   ATCC; CRL-3439
DR   cancercelllines; CVCL_A4AM
DR   Wikidata; Q105511866
RX   PubMed=27378269;
CC   Population: Caucasian.
CC   Doubling time: ~1 week (ATCC=CRL-3439).
CC   Selected for resistance to: ChEBI; CHEBI:41774; Tamoxifen.
CC   Sequence variation: Mutation; HGNC; 5173; HRAS; Simple; p.Glu162Lys (c.484G>A); ClinVar=VCV001034833; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Leu108Arg (c.323T>G); Zygosity=Homozygous (from parent cell line).
CC   Omics: Deep exome analysis.
CC   Derived from site: Metastatic; Ascites; UBERON=UBERON_0007795.
DI   NCIt; C4194; Invasive breast carcinoma of no special type
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0588 ! ZR-75-1
SX   Female
AG   63Y
CA   Cancer cell line
DT   Created: 12-01-21; Last updated: 02-05-24; Version: 7
RX   PubMed=27378269; DOI=10.1186/s12885-016-2452-5;
RA   Kangaspeska S., Hultsch S., Jaiswal A., Edgren H., Mpindi J.P.,
RA   Eldfors S., Bruck O., Aittokallio T., Kallioniemi O.-P.;
RT   "Systematic drug screening reveals specific vulnerabilities and
RT   co-resistance patterns in endocrine-resistant breast cancer.";
RL   BMC Cancer 16:378.1-378.17(2016).